- Home
- PULM vs BNR Comparison
PULM vs BNR Comparison
Compare PULM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- BNR
- Stock Information
- Founded
- PULM 2003
- BNR 2014
- Country
- PULM United States
- BNR China
- Employees
- PULM N/A
- BNR N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- PULM Health Care
- BNR Health Care
- Exchange
- PULM Nasdaq
- BNR Nasdaq
- Market Cap
- PULM 33.2M
- BNR 38.3M
- IPO Year
- PULM N/A
- BNR 2020
- Fundamental
- Price
- PULM $5.62
- BNR $6.80
- Analyst Decision
- PULM
- BNR
- Analyst Count
- PULM 0
- BNR 0
- Target Price
- PULM N/A
- BNR N/A
- AVG Volume (30 Days)
- PULM 11.2K
- BNR 52.8K
- Earning Date
- PULM 08-12-2025
- BNR 08-21-2025
- Dividend Yield
- PULM N/A
- BNR N/A
- EPS Growth
- PULM N/A
- BNR N/A
- EPS
- PULM N/A
- BNR N/A
- Revenue
- PULM $1,921,000.00
- BNR $72,112,038.00
- Revenue This Year
- PULM N/A
- BNR $136.32
- Revenue Next Year
- PULM $134.88
- BNR N/A
- P/E Ratio
- PULM N/A
- BNR N/A
- Revenue Growth
- PULM N/A
- BNR 0.53
- 52 Week Low
- PULM $1.78
- BNR $2.18
- 52 Week High
- PULM $10.40
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- PULM 32.49
- BNR 67.23
- Support Level
- PULM $5.60
- BNR $4.47
- Resistance Level
- PULM $6.15
- BNR $9.48
- Average True Range (ATR)
- PULM 0.28
- BNR 0.74
- MACD
- PULM -0.05
- BNR 0.36
- Stochastic Oscillator
- PULM 1.63
- BNR 55.11
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.